Navigation Links
Jubilant Enters Research Collaboration With AstraZeneca
Date:5/5/2009

NOIDA, India, May 5 /PRNewswire/ --

- Research Collaboration to Provide AstraZeneca With New Preclinical Drug Candidates

Jubilant Organosys Ltd, headquartered in India, announced today that its Bangalore, India, based subsidiary,Jubilant Biosys Ltd, has signed a research collaboration agreement with, AstraZeneca, and focused on delivering novel drug candidates into the international pharmaceutical company's pre-clinical pipeline. Under the shared risk-reward collaboration, which will initially focus on the neuroscience area, Jubilant aims to deliver a steady stream of discovery programs to AstraZeneca.

AstraZeneca will own the compounds developed under the collaboration with worldwide development and commercialization rights. Jubilant will be eligible to receive research funding spanning an initial five-year period. In addition, AstraZeneca will also pay Jubilant success-based development milestones, as well as royalties based on successful global commercialization of any of the compounds.

Commenting on this Collaboration, Mr. Shyam S Bhartia, Chairman & Managing Director and

Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Organosys Ltd, said: "We are very pleased to partner with AstraZeneca, this collaboration will leverage the innovative capabilities of AstraZeneca and Jubilant Biosys in providing a robust global drug discovery model. Through this partnership, Jubilant is confident of contributing to AstraZeneca's preclinical portfolio and anticipates significant rewards from successful downstream milestones. This partnership furthers Jubilant's strategy to be India's largest provider of innovative and integrated pharmaceutical solutions, enabling the global pharmaceutical industry's quest to discover affordable innovative medicines."

Jan Lundberg, Executive Vice-President, Global Discovery, at AstraZeneca says, "This collaboration complements our internal capabilities and increases the capacity of our pre-clinical programs. It is a concrete example of the innovative approaches we are taking to deliver a sustainable Discovery pipeline with a lean and agile organization. Ultimately, this will provide us with more shots on goal as we look to sustain a competitive portfolio and provide meaningful medicines to patients."

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit: http://www.astrazeneca.com

About Jubilant Biosys

Jubilant Biosys Ltd., a subsidiary of Jubilant Organosys Ltd.,provides integrated drug discovery and development solutions to the global pharmaceutical industry. Jubilant Biosys has an integrated state of the art facility in Bangalore. The Center houses over 300 scientists specializing in multiple disciplines to include Discovery biology, medicinal chemistry, structural biology, pharmacology, toxicology, pharma chem, molecular modeling, crystallography and information technology supporting discovery efforts.

For more information please visit: http://www.jubilantbiosys.com

About Jubilant Organosys

Jubilant Organosys Ltd. is an integrated pharmaceutical industry player, one of the largest custom research and manufacturing services (CRAMS) and drug discovery and development services companies out of India. The company has a presence across the pharmaceutical value chain for products and services such as proprietary products ,exclusive synthesis, active pharmaceutical ingredients, contract manufacturing of sterile injectables (liquids and lyophilized) products, non-steriles (ointments, creams and liquid) and radiopharmaceuticals, drug discovery services, medicinal chemistry services, clinical research services, generic dosage forms and healthcare. Jubilant Organosys has geographically diversified manufacturing facilities at ten locations worldwide. Together, these help Jubilant cater to 150 customers across more than 50 countries around the world.For more information please visit: http://www.jubl.com

Disclaimer:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Organosys may, from time to time, make additional written and oral forward looking statements, including statements contained in the Company's filings with the regulatory bodies and its reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

    For further information contact:

    For Media:
    Seema Ahuja
    Jubilant Organosys Limited
    Ph:     +91-120-4361062
    Mobile: +91-9810631779
    email:seema_ahuja@jubl.com

    For Business Queries: Europe and APAC:
    Saurabh Kapure
    Senior Manager Business Development
    Jubilant Biosys and Jubilant Chemsys Ltd.
    Direct: +91-80-6662-8852
    e-mail: saurabh_rk@jubilantbiosys.com

    For Investors:
    Deepak Malik
    Jubilant Organosys Limited
    Tel: +91-120-4361114
    Fax: +91-120-2516629
    E-mail: deepak_malik@jubl.com

    For Business Queries: USA
    Corey Jacklin
    Director, Business Development
    Jubilant Biosys
    Tel: +1-215-369-0965
    E-mail: Corey_Jacklin@jubilantbiosys.com


'/>"/>
SOURCE Jubilant Organosys Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
2. Elusys Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
3. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
4. Another LNA-based RNA Inhibitor Enters Clinical Trials
5. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
6. ESBATechs Antibody Fragment Enters Phase Ib/IIa in Ophthalmology
7. ESBATechs Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity
8. ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers
9. PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate
10. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
11. Pharmaleads Lead Candidate for Pain, PL37, Enters Phase I
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... 6, 2017   Provista, a proven leader ... billion in purchasing power, today announced a new resource ... The Newsroom is the online home for case ... expert bios, news releases, slideshows and events. ... wealth of resources at their fingertips, viewers can also ...
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
(Date:10/2/2017)... PHILADELPHIA , Oct. 2, 2017 Halo Labs announces ... particle analysis system called the HORIZON at MIBio 2017 in ... analyzes subvisible and visible particulate matter in biopharmaceutical samples with unprecedented ... use of the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The Visiting ... Day Market. Featuring a collection of specialty vendors and unique items from across the ... and quality-focused health and wellness services offered by the VNA. The boutique will ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob ... sciatica in a new episode of "Success Files," which is an award-winning educational ... and investigates each subject in-depth with passion and integrity. , Sciatica occurs when ...
(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
Breaking Medicine News(10 mins):